(SAPA-NE)
SAPA-NE 10th Scientific Symposium
Drug Discovery& Development: From Small Molecules to Biotherapeutics
Co-hosted by the MIT Talent and Economic Forum
Saturday, February 24th, 2007
1:00 pm-6:00 pm
Tang Center, Building E51, Room 315
Sloan Business School, MIT
Purpose:
1.For beginners in drug discovery, this is a symposium to help you to understand drug discovery, including the areas of translational research, kinases and analytical development;
- For veterans in drug discovery, this is a symposium that you can know current trend in above areas.
Who should attend:
- SAPA members (we accept onsite membership registration)
- General publics with interest in drug discovery
1:00-1:30 Registrations
1:30-1:40Opening remarks, Jun Jun Wu, Ph.D., Present-Elect
1:40-2:30M. Isabel Chiu, Ph.D., Senior Director, Translational Research,
AVEO Pharmaceuticals Inc.
“Genetically Engineered Models in Translational Research: from Target Identification to Response Prediction”
2:30-3:20Boke Zhang, Ph.D. Director of Analytical Development, Millennium Pharmaceuticals.
“Analytical Development in Drug Product Development”
3:20-3:40Coffee break and networking
3:40-4:30Jessie English, Ph. D., director, Pfizer Kinase Center of Emphasis
“The Pfizer Kinase Center of Emphasis: Unleashing the Kinome for Drug Discovery”
4:30-5:20Erxi Wu, Ph.D.,Principal Investigator, Children's Hospital Informatics Program, Health Sciences and Technology of Harvard-MIT, Harvard Medical School
“Mechanisms of Anticancer Natural Products”
5:20-5:25Jun Han, Ph.D., President, SAPA-NE
6:00-8:00 Dinner reception with speakers and the symposium organizers
Dinner Reception:
Royal East
792 Main St
Cambridge,MA02139-3510
(617) 661-1660
$15 per person. Seats are limited. Dinner tickets and directions to the restaurant are available at the registration desk.
Registration (excluding dinner reception):
Free to current SAPA members and college students with valid ID, $10 for others.
Directions and parking:
Please find the directions to Tang Center (Building E51) from the attached MIT campus map
Wong Auditorium
The Jack C. Tang Center for Management Education/Building E51
Sloan Business School of MIT
2 Amherst Street
Cambridge, MA 02142-1310
By T: Red line, Kendal Square/MIT; by Bus: #1, MIT or #77, 47, 83 at Kendal Square.
By Car: From 90, exit 18, follow the direction to Cambridge, stay on Memorial Drive, turn left onto Wadsworth St, turn left onto Amherst St.
From 93, exit 26 to storrow drive and drive about 2 miles and exit to 2A/Harvard Bridge, pass the bridge and turn right onto Memorial Drive, turn left onto Wadsworth St, turn left onto Amherst St.
Plenty of free parking available on campus parking lots (Access to Sloan lot from Main St. or Hayward lot from Hayward St.)
Contacts:
Dr. Min Wu, Aveo Pharmaceuticals, Inc. , (617) 299-5938
Dr. Zhao-Kui Wan, Wyeth Research, , (617) 665-5635 (office)
Dr. Yihan Wang, ARIAD Pharmaceuticals, Inc., (617) 494-0400
Biography of invited speakers
M. Isabel Chiu, Ph.D. Senior Director, Translational Research, AVEO Pharmaceuticals Inc., Cambridge, MA
Dr. Chiu joined AVEO Pharmaceuticals Inc. three years ago to establish a robust cancer target pipeline, adapting AVEO’s inducible tumor models for comprehensive, large-scale genetic screens to identify novel, cancer-relevant targets. At the same time, her group is also developing genetically defined, model tumor archives as the basis for establishing genetic correlations of response in tumor populations for translational research. Currently Dr. Chiu heads two multi-year research collaborations with Merck Research Laboratories.
Dr. Chiu joins AVEO after ten years at GPC-Biotech, formerly Mitotix Inc., where she most recently served as Director of Target Discovery. While at Mitotix and GPC-Biotech, she established phenotypic screening programs for oncology using retroviral libraries in human tumor cells, including synthetic lethality screens for the identification of tumor-specific candidate targets. This work formed the basis for a multi-year external alliance with Atlana Pharma Inc. and was the cornerstone for a second alliance with Altana Research Institute. Dr. Chiu originally joined Mitotix to study the effects of rapamycin on the cell cycle, pioneering the use of yeast three-hybrid screens in discovery research. Over the years Dr. Chiu contributed to other oncology collaborations including Dupont-Merck and Genetica Inc., and is the author of numerous publications and issued patents. Dr. Chiu received her BA in Biochemistry from Brandeis University, her Ph.D. in Biology from Massachusetts Institute of Technology and post-doctoral training at the Johns Hopkins School of Medicine and Howard Hughes Medical Institute.
Boke Zhang, Ph.D. Director of Analytical Development, Millennium Pharmaceuticals, Cambridge, MA.
Dr. Zhang was the Associate Director and Site Head of Analytical R&D of Baxter’s Cherry Hill site in NJ. Prior to that, he was the Senior Manager of Global Analytical Development of Pfizer in Chicago. He has more than 18-year pharmaceutical industry experience in developing drug candidates from discovery through development to commercial. His work experience includes HuaBei Zhi Yao (华北制药) in China, Novopharm (now Teva Pharmaceuticals) and Apotex in Canada, Pfizer / Baxter and Millennium in US. His area of expertise includes method development and validation, tech transfer, quality control, FDA inspection and regulatory submissions (CMC) from phase 0 to 4 product development in both non-GxP and GxP environments.
Representative Products Developed and Approved onto Market (NDAs) include Celebrex ® (oral solid), Granisetron ® (injectable), Synarel ® (nasanyl metered-dose), Inspra ® (Eplerenone), Covera – HS ® , Daypro ®; Development Candidates (phase 1-3, INDs) MLN518, 897/701, 415, 8054, 8237, 4924, 6095, 0002, 1202; Many generic products (ANDAs) ranitidine, misoprostol, doxazosin, paroxetine, arthrotec, verapamil HCl.
Dr. Zhang received his Ph.D. degree in organic chemistry from University of Western Ontario, Canada in 1993, M.Sc. degree in biochemistry and B.Sc. degree in organic chemistry from Lanzhou University in China in 1986 and 1983, respectively.
Jessie M. English, Ph.D., Director, Pfizer Kinase Center of Emphasis, Research Technology Center (RTC), Cambridge, MA.
Dr. English received her B.S. in Biochemistry from Kansas State University followed in 1991 by a Ph.D. in Neurobiology from the University of North Carolina at Chapel Hill. Dr. English continued her training with Dr. Melanie Cobb at the University of Texas Southwestern Medical Center in Dallas, TX. In Dr. Cobb’s laboratory Dr. English identified and characterized a novel MAPK pathway, the MEK5 MAPK pathway. In addition, during her postdoctoral fellowship she was the first to identify clones encoding the WNK family of protein kinases, which are now known to be mutated in some forms of hereditary hypertension.
In 1998 Dr. English joined the Tumor Biology Department at Schering-Plough Research Institute (SPRI) in Kenilworth NJ. At SPRI she was the project leader for multiple early discovery stage kinase inhibitor programs. She also established and chaired the SPRI Protein Kinase Working Group. In addition to traditional drug discovery, Dr. English also continued her work on kinases and MAPK signaling pathways while at SPRI. This work led to multiple publications including the first published curation of protein kinases in the human genome as well as an elucidation of the ERK1,2 transcriptome in mammary epithelial cells.
Dr. English joined Pfizer in August 2004 to head the newly formed Kinase Center of Emphasis at the Research Technology Center in Cambridge, MA. In this role she is responsible for directing the development of a PGRD-wide platform to increase efficiency in PGRD’s prosecution of kinases. In addition she leads, through a matrix role, the efforts of the Kinase CoE to partner with researchers across PGRD in early stage drug discovery to develop and provide innovative tools, technologies, and approaches for targeting kinases.
Erxi Wu, Ph.D. Principal investigator, Children's Hospital Informatics Program at Health Sciences and Technology Division, Harvard-MIT, Cambridge, MA.
Dr. Wu’s research areas include cancer research, cancer therapeutics, drug discovery, functional genomics and bioinformatics. He received his Ph.D. in Molecular Medicine from University of Sheffield. He did his postdoctoral training in Dana Farber Cancer Institute, Harvard Medical School for more than 6 years. He worked in Hunan Institute for Drug Control as Pharmacist and Pharmacist-in-Charge for more than 10 years. He was a visiting fellow in University of London for one year and a guest lecturer in Hunan University for one year. He served for a few professional originations such as President of International Association of Biological and Medical Research (IABMR), Vice President of Sino-American Pharmaceutical Professional Association (SAPA), and President of SAPA-New England. He received numerous awards include Sino-British Friendship Scholarship Scheme Scholarship, British Government Overseas Research Scholarship, NLM fellowship, SAPA Outstanding Contribution Award and IABMR Outstanding Contribution Award.
SAPA-NE 2007 Scientific Symposium Organizing Committee
Yihan Wang, Ph. DPrincipal Scientist
ARIAD Pharmaceuticals, Inc.
Tel: 617-494-0400
Email: / Zhao-Kui Wan, Ph.D.
Principal Research Scientist
Wyeth Research
Tel: 617-665-5635
Email:
Min Wu, Ph. D
Senior Scientist
AVEO Pharmaceuticals, Inc
Tel: 617-299-5938
Email: / Bing Zhang, Ph.D.
Team Leader
ArQule, Inc.
Tel: 617-665-5655
Email:
Yuan-Hua Ding, Ph.D.
Head, Structural Biology
Pfizer Research Technology Center
Tel: 617-551-3168
Email: